论文部分内容阅读
CI-973化学名[SP-4-3-(R)]-[1,1-环丁烷二羧酸基-(2-)][2-甲基-1,4-丁二氨基-N,N’]合铂(Ⅱ),是一种新的铂类抗肿瘤药。本文对它进行了几种临床前模型系统的抗肿瘤活性研究。体外实验主要对耐顺铂及对顺铂敏感的小鼠白血病细胞进行了研究,并把CI-973与其它的铂类药物顺铂、卡铂进行了活性比较,对顺铂敏感的细胞系L1210及P388,CI-973的ID50浓度(_μM)分别为1.4和0.71;而顺铂则为1.03和0.43;卡铂为7.6和3.2。这表明CI-973的活性强度高于卡铂而低于顺铂。对耐顺
CI-973 Chemical name [SP-4-3- (R)] - [1,1-cyclobutanedicarboxylic acid- (2 -)] [2-methyl-1,4-butanediamino-N , N ’] platinum (Ⅱ), is a new platinum anti-tumor drug. This article has carried out several preclinical model systems for its antitumor activity. In vitro experiments mainly on cisplatin and cisplatin-sensitive mouse leukemia cells were studied and CI-973 and other platinum drugs cisplatin, carboplatin were compared activity of cisplatin-sensitive cell line L1210 And ID50 concentrations (_μM) for CI-973 and P388 were 1.4 and 0.71, respectively; while for cisplatin 1.03 and 0.43; for carboplatin 7.6 and 3.2. This suggests that CI-973 is more active than carboplatin and less cisplatin. On the resistance